Evidence map›Paper›PMID 33523240›Full record

ArticleDer Urologe. Ausg. A2021

[Apps and web-based interventions for prostate cancer follow-up-a scoping review].

S C Pornak, A Papachrysanthou, B Lehr

Abstract readScoping Review
PubMed Publisher
In one paragraph

Article in Der Urologe. Ausg. A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

S C PornakInstitut für eHealth und Management im Gesundheitswesen, Hochschule Flensburg, Kanzleistraße 91-93, 24943, Flensburg, Deutschland. shirin.caroline.pornak@hs-flensburg.de.
A PapachrysanthouInstitut für eHealth und Management im Gesundheitswesen, Hochschule Flensburg, Kanzleistraße 91-93, 24943, Flensburg, Deutschland.
B LehrInstitut für eHealth und Management im Gesundheitswesen, Hochschule Flensburg, Kanzleistraße 91-93, 24943, Flensburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSide effects due to prostate cancer therapy and psychosocial strain are not always recognised during follow-up, which may result in the absence of appropriate therapy offers. Recent studies have shown a potential for improving care by integrating digital technologies like smartphone apps.

objectiveThis scoping review aimed to explore the effects of apps for the assessment of side effects and distress, provision of individualised patient information and management of prostate cancer follow-up on patient outcome. Furthermore, findings on user acceptance and recommendations for implementation and evaluation were identified.

methodsThe databases MEDLINE, Web of Science, PsycInfo, Cochrane Library, ScienceDirect, PSYNDEX, wiso and SpringerLink were searched for quantitative and qualitative primary studies from the period 2005 until August 2020.

resultsIn all, 22 studies were included in the review. Apps and web-based interventions had a positive effect on physical symptoms, psychosocial distress and participation in treatment. User acceptance was predominantly good, but there were still substantial numbers of non-users.

conclusionsApps and web-based interventions can be an effective supplement to follow-up care, especially if they are adapted to individual patient needs. Robust evidence is still lacking. There is a need for larger randomised controlled studies, particularly in the German healthcare setting.

Indexed as

Internet-Based InterventionMobile ApplicationsProstatic NeoplasmsFollow-Up StudiesHumansMalemHealthPatient reported outcome measuresProstate cancerSelf managementSide effects

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.